FDA Proposes Antihypertensive Class Indication For Reducing CV Events

Adding an indication for reducing cardiovascular adverse event risk is one option FDA will have its Cardiovascular & Renal Drugs Advisory Committee consider for antihypertensive class labeling June 15. Other class labeling options offered in FDA briefing document would amend the clinical trials section.